Jasperate
Early Stage
Reduce Pain and Suffering Caused by Trigger Finger
Overview
Raised: $100,000
Total Commitments ($USD)
Platform
StartEngine
Start Date
10/02/2017
Close Date
12/28/2017
Min. Goal
$10,000
Max. Goal
$100,000
Min. Investment
$100
Security Type
Equity - Common
Funding Type
RegCF
Price Per Share
$1.00
Pre-Money Valuation
$500,000
Rolling Commitments ($USD)
Status
Funded
Reporting Date
12/31/2017
Days Remaining
Funded
% of Min. Goal
1,000%
% of Max. Goal
100%
Likelihood of Max
Funded
Avg. Daily Raise
$1,149
# of Investors
148
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location
Lisle, Illinois
Industry
Healthcare & Pharmaceuticals
Tech Sector
Needles. Nothing like a baby screaming at a doctor’s office to be reminded of how much you don’t like shots. Sometimes though, they’re unavoidable. That’s especially true for people with trigger finger. Trigger finger is when a tendon in finger becomes inflamed leading to stiffness, a popping or clicking sensation, or the finger becoming locked when bent. Relief often only comes through an (often painful) injection. Shudder, shudder.
That’s where (insert drumroll here please) J-needle comes into play. Using a patent-pending curved needle, the J-needle doesn’t directly pierce the tendon of the inflamed finger. Instead, it enters at an angle, saving both the patient and doctor time, improving accuracy of the medical procedure, and providing the patient with immediate relief. In fact, Jasperate claims that, with the J-needle, doctors can double the amount of trigger fingers treated in a given session. Bam!
Considering that there are 200,000 new cases of trigger finger reported each year, that’s a pretty big deal. Ten percent of diabetics get it, 2-3% of people with it get it randomly. With the population aging and becoming more obese, those numbers (unfortunately) are going to keep rising. In addition to trigger finger, the J-needle can also be used to treat for joint pain, in plastic surgery, neurology, anesthesiology, eye injections...the list goes on. It’s like the superhero of needles.
Founder and Chief Medical Advisor, Dr. Stephen Soloway, has been a doctor for the past 30 years and has earned Top Doctor Awards every year since 2003. The J-needle came out of his experience working with traditional needles and seeing that a change needed to happen. CEO David Weksel and COO Charles Brunner both have extensive leadership experience at companies such as Accenture and SharkNinja, and none of the principal employees will take a salary until revenue is recognized.
J-needles seem to be the only needle of its kind, and with more waistlines expanding and more fingers locking, there is definitely a need for it. Jasperate just might be the pinprick you’ve been looking for to take a stab at a medical investment.
That’s where (insert drumroll here please) J-needle comes into play. Using a patent-pending curved needle, the J-needle doesn’t directly pierce the tendon of the inflamed finger. Instead, it enters at an angle, saving both the patient and doctor time, improving accuracy of the medical procedure, and providing the patient with immediate relief. In fact, Jasperate claims that, with the J-needle, doctors can double the amount of trigger fingers treated in a given session. Bam!
Considering that there are 200,000 new cases of trigger finger reported each year, that’s a pretty big deal. Ten percent of diabetics get it, 2-3% of people with it get it randomly. With the population aging and becoming more obese, those numbers (unfortunately) are going to keep rising. In addition to trigger finger, the J-needle can also be used to treat for joint pain, in plastic surgery, neurology, anesthesiology, eye injections...the list goes on. It’s like the superhero of needles.
Founder and Chief Medical Advisor, Dr. Stephen Soloway, has been a doctor for the past 30 years and has earned Top Doctor Awards every year since 2003. The J-needle came out of his experience working with traditional needles and seeing that a change needed to happen. CEO David Weksel and COO Charles Brunner both have extensive leadership experience at companies such as Accenture and SharkNinja, and none of the principal employees will take a salary until revenue is recognized.
J-needles seem to be the only needle of its kind, and with more waistlines expanding and more fingers locking, there is definitely a need for it. Jasperate just might be the pinprick you’ve been looking for to take a stab at a medical investment.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.